Home / Articles posted by Peter Göttel

Author: Peter Göttel

New Paper: The DNA-Based Drug BC 007 neutralizes agonistically acting autoantibodies directed against G protein–coupled receptors

Müller et al. (2019) The DNA-Based Drug BC 007 Neutralizes Agonistically Acting Autoantibodies Directed Against G Protein–Coupled Receptors -Successful Mode of Action Demonstrated in Clinical Phase 1 Trial. Chemistry Today March/April 37(2), 65-67 Read the abstract here and read full text article here download full text article
Read More

NEWS: Berlin Cures’ Steering Committee is Assembled to Facilitate the Design and Implementation of Phase 2 Study of BC 007

ZUG, Switzerland, Dec. 6, 2018 /PRNewswire/ -- Swiss drug developer Berlin Cures Holding AG today announced the establishment of a steering committee of renowned cardiologists focused on ensuring expert input during the design and implementation of the Phase 2 study of BC 007 for the treatment of dilated cardiomyopathy. "By convening an international team of experts to provide guidance around t...
Read More

NEWS: Berlin Cures Announces Successful Completion of Phase 1 Study of BC 007 for the Treatment of Cardiomyopathy

ZUG, Switzerland, Aug. 22, 2018 /PRNewswire/ -- Drug developer Berlin Cures today announced the successful completion of its Phase 1 study of BC 007, a DNA-based aptamer compound that binds to and eliminates functional pathogenic autoantibodies for the treatment of cardiomyopathy. "The safety profile of BC 007 continues to be excellent," said Dr. Johannes Müller, founder and president of the Bo...
Read More

NEWS: Berlin Cures Announces Formation of Scientific Advisory Board

Berlin Cures Announces Formation of Scientific Advisory Board Inaugural Members Include Leading Experts in Cardiology and Autoimmunity ZUG, Switzerland, May 23, 2018 /PRNewswire/ -- Drug developer Berlin Cures today announced the formation of a Scientific Advisory Board (SAB) and the appointment of its first two members, Prof. Beda M. Stadler and Prof. Wilhelm Vetter, to help advance the cli...
Read More

NEWS: Heart Failure Treatment from Berlin Cures Shows Promise in Phase 1 Study

BC007 Eliminates Autoantibodies Linked to Disease in 80% of Patients First Drug to Attack the Cause of Dilated Cardiomyopathy ZUG, Switzerland, and BERLIN, Feb. 26, 2018 – The first drug designed to eliminate autoantibodies that are a major cause of heart failure and to treat heart failure symptoms was effective and well-tolerated in a Phase 1 clinical study, according to an oral presentatio...
Read More

Berlin Cures Set to Launch Phase 2 Study of Heart Failure Drug

Berlin Cures Set to Launch Phase 2 Study of Heart Failure Drug BC007 Neutralizes Autoantibodies That Cause 80% of Dilated Cardiomyopathy ZUG, Switzerland, and BERLIN, Germany, January 7, 2018 – A drug designed to neutralize autoantibodies linked to heart failure is set to begin Phase 2 testing early in 2018, the drug’s developer, Berlin Cures, said today. The double-blind study will eva...
Read More
Top